ER+, HER2-, metastatic breast cancer

Clinical trials for ER+, HER2-, metastatic breast cancer explained in plain language.

Never miss a new study

Get alerted when new ER+, HER2-, metastatic breast cancer trials appear

Sign up with your email to follow new studies for ER+, HER2-, metastatic breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 3 Not yet recruiting 1 Not yet finished but already full! 1

Breast cancer drug study looks at body fat changes

Knowledge-focused Ongoing

This study looks at how three common breast cancer drugs (abemaciclib, ribociclib, or palbociclib) change body fat and muscle in 30 people with ER+/HER2- breast cancer that has spread. Participants get CT and DEXA scans before and after 24 weeks of treatment. The goal is to under…

Matched conditions: ER+, HER2-, METASTATIC BREAST CANCER

Sponsor: Montefiore Medical Center • Aim: Knowledge-focused

Last updated Jun 27, 2026 13:00 UTC

ER+, HER2-, metastatic breast cancer

Get alerted when new ER+, HER2-, metastatic breast cancer trials appear

Breast cancer drug study looks at body fat changes